Global Semiconductor Stepper Equipment Market 2012-2016

TechNavio's analysts forecast the Global Semiconductor Stepper Equipment market to grow at a CAGR of 12.37 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for integration and contraction of semiconductor devices. The Global Semiconductor Stepper Equipment market has also been witnessing a reduction in the chip size. However, the cyclical nature of the Semiconductor industry could pose a challenge to the growth of this market.

TechNavio's report, the Global Semiconductor Stepper Equipment Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas and the APAC and EMEA regions; it also covers the Global Semiconductor Stepper Equipment market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include ASML Holding N.V., Canon Inc., and Nikon Corp.

The other vendors mentioned in this report are Cymer Inc., GlobalFoundries Inc., Intel Corp., Semiconductor Manufacturing International Corp., Samsung Group, Taiwan Semiconductor Manufacturing Co. Ltd., United Microelectronics Corp., and Ultratech Inc.


Key questions answered in this report:

* What will the market size be in 2016 and at what will be the growth rate?

* What are key market trends?

* What is driving this market?

* What are the challenges to market growth?

* Who are the key vendors in this market space?

* What are the market opportunities and threats faced by key vendors?

* What are the strengths and weaknesses of each of these key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details provided within the report.

To order this report:

Global Semiconductor Stepper Equipment Market 2012-2016 

Email: support@researchonglobalmarkets.com
US:  +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE:  Researchonglobalmarkets.com

RELATED VIDEO:

Global Smart Grid Managed Services Market 2012-2016

TechNavio's analysts forecast the Global Smart Grid Managed Services market to grow at a CAGR of 51.29 percent over the period 2012-2016. One of the key factors contributing to this market growth is the emergence of smart grids. The Global Smart Grid Managed Services market has also been witnessing an increasing support for the Smart Grid industry from numerous governments. However, the commercial mind-set of various power utilities could pose a challenge to the growth of this market.

TechNavio's report, the Global Smart Grid Managed Services Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in North America, Western Europe, and the APAC region; it also covers the Global Smart Grid Managed Services market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space include Accenture plc, Capgemini S.A., GE Energy LLC, IBM Corp., Lockheed Martin Corp., and Siemens AG.

The other vendors mentioned in this report are AT&T Inc., Infosys Ltd., Tendril Networks Inc., Alcatel-Lucent USA Inc., EnerNOC Inc., Ericsson Inc., FirstCarbon Solutions Corp., HCL Technologies Ltd., Itron Inc., Trilliant Energy Services Inc., Verizon Communications Inc., and Wipro Ltd.

Key questions answered in this report:

* What will the market size be in 2016 and at what will be the growth rate?

* What are key market trends?

* What is driving this market?

* What are the challenges to market growth?

* Who are the key vendors in this market space?

* What are the market opportunities and threats faced by key vendors?

* What are the strengths and weaknesses of each of these key vendors?

* You can request one free hour of our analysts time when you purchase this market report.

Details provided within the report.

To order this report:

Global Smart Grid Managed Services Market 2012-2016 

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED VIDEO:

Analytical Tool - Apoptosis in Oncology

"Analytical Tool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:

Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others.

Apoptosis in Oncology: Pipeline Update 2013.

The Package Includes:

* A progress analysis on current and emerging drugs

* Information on most companies active in apoptotic drug R&D

* Information on key industry related apoptotic drug projects

* Data from most important clinical trials

* Information on early developmental stage projects

* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

* Tracking cutting edge companies, therapies and new technologies

* Rapid identification of partners & competitors

* Laying down a comprehensive framework for further analysis of the field

* Producing presentations surrounding the development of apoptotic drugs in oncology

* Identifying emerging apoptotic cancer products & key areas of pharmaceutical R&D 

This software application is a searchable database reflects the most recent advances in the field of apoptotic cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker Group's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker Groups software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Apoptosis in Oncology

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED VIDEO :

Analytical Tool - Leukemia

"Analytical Tool - Leukemia" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers - A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market and Leukemia Drug Pipeline Update 2013.

The Package Includes

* A progress analysis on current and emerging drugs

* Information on most companies active in leukemia R&D

* Information on key industry related leukemia projects

* Data from most important clinical trials

* Information on early developmental stage projects

* Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

* Tracking cutting edge companies, therapies and new technologies

* Rapid identification of partners & competitors

* Laying down a comprehensive framework for further analysis of the field

* Producing presentations surrounding the development of leukemia therapeutics

* Identifying emerging leukemia products & key areas of pharmaceutical R&D

This software application is a searchable database reflects the most recent advances in the field of leukemia drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeekers software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Leukemia

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

RELATED VIDEO :

Analytical Tool - Lung Cancer

Analytical Tool - Lung Cancer is a premium combo product of "Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market" and "Lung Cancer Drug Pipeline Update 2013".

According to market analytical studies, the therapeutic lung cancer drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau. Indeed, both Avastin and Efaproxyn have generated exciting data.

This combo product assists in your strategic planning decisions in oncology drug development. Understand the clinical and strategic challenges towards the commercialization of drugs in lung cancer treatments. Assess opportunities and risks for the continued development of innovative developmental treatments.

Find out more about each product by clicking on respective links.

This software application is a searchable database reflects the most recent advances in the field of lung cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeekers software applications give better overview, specific search capabilities and great dynamic reports.

To order this report:

Analytical Tool - Lung Cancer

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com



RELATED VIDEO

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations have raised the bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future.

Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed Alios VX-135 in 2012 for total of $775m, and Abbott in-licensed Enantas ABT-450 for total of $310m. In the next spurt of M&A in this sector, we expect companies which offer differentiated MOA to be in the limelight, are (i) Alleviate the need for Ribavarin, (ii) Address resistance, non-responders, Liver cirrhosis, HIV-HCV -co infection etc, (iii) Target other genotypes, and (iv) Vaccines or Boosters of immune system (toll like receptors). In this report, we have analyzed the novel pipeline candidates, which target unmet needs, offer promise of an all oral IFN-free treatment with at par or better efficacy / compliance, and novel vaccine candidates.

Table of Contents.

1.      Executive Summary

2.      Progress in the Clinical Development of HCV drugs

·       Noteworthy progress in the Oral IFN -Free combinations for Treatment of HCV

·       Options for the most Challenging Patient Subtypes in HCV

·       IFN intolerant and other Genotypes

·       Hepatitis C Virus Prevalence in ROW 

3.      Competitive Landscape - IFN-Free drugs

·       Gilead: Sofosbuvir/GS-5885

·       Abbott: ABT-450r/ABT-472/ABT-333

·       Boehringer Ingelheim: Faldaprevir/BI 207127

·       Medevir: Simeprevir

·       Vertexs VX-135

·       Bristol-Myers: Daclatasvir/Asunaprevir

·       Merck: MK-5172/MK-8742

4.      Market Dynamics- Present and Future

·         Present- Launch of Protease Inhibitors: Sunset Sooner Than Expected.

·         Future- the Best-in-Class IFN-Free Oral Pill for HCV

5.      HCV Vaccines

·         GlobeImmune

·         Okairos

·         ChronTech Pharma/ Inovio

·         Transgenes TG4040

·         Profectus Biosciences HCV vaccine

·         Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

6.      HCV-HIV Co-infection

·         Effects of co-infection

·         Companies targeti ng HIV-HCV Co-infection

7.      ANNEXURE

·         Figures - Designs of ongoing IFN-free PhIII trials

·         Table - Data from IFN-free combinations

·         Table - Viral response in genotype-1 patients - IFN-combinations

·         Key Abstract presented at AASLD 12

To order this report: 

Therapeutic Class Report Overview : Hepatitis C Virus Infection

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

Related Video

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

Targeting kinases have been on the agenda of most drug developers/ researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer. Resistance to existing therapies develops as cancer cells bypass these efforts and their remains an evergreen search for new targets to meet these challenges. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years.

This report (ToC attached) highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors (PCYC, INFI, CRIS, SymBio, GILD), the clinical data and competition.

KEY POINTS DISCUSSED IN THE REPORT

Drugs in the pipeline

* PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

* Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

* BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

* M&A in Kinase Inhibitors in the last 5 years

* Related Milestones/catalysts in 2013-14

* Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.

* Ongoing Clinical Trials of Companies Covered

Detailed Reports on – 

* Curis (CRIS) - Time to Assess Value Beyond Erivedge!

* Gilead (GILD) - New HIV + HCV Products to Sustain the Growth Trajectory

* Infinity pharma (INFI) - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity! 

* Pharmacyclics (PCYC) - Ibrutinib - Promising to Deliver More

* SymBio (4582) - Significant Upside still Remains: Bendamustine + Rigosertib + Cash to In-license More!

To order this report:

Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

Email: support@researchonglobalmarkets.com

US:  +1 866 325 7446

UK: +44 203 514 2363

India: +91 22 4098 7600

SOURCE:  Researchonglobalmarkets.com

Related Video: